Cargando…
Line-probe assay and molecular typing reveal a potential drug resistant clone of Mycobacterium tuberculosis in Ethiopia
BACKGROUND: Antimicrobial resistance is a global concern of increasing significance. Multidrug resistant tuberculosis (MDR-TB) is spreading worldwide. It is important to monitor trends of antimycobacterial resistance. This is particularly true for high TB burden countries such as Ethiopia where disp...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280437/ https://www.ncbi.nlm.nih.gov/pubmed/30534412 http://dx.doi.org/10.1186/s40794-018-0075-3 |
_version_ | 1783378672547266560 |
---|---|
author | Bekele, Shiferaw Derese, Yohannes Hailu, Elena Mihret, Adane Dagne, Kifle Yamuah, Lawrence Hailu, Tsegaye Ayele, Samuel Beyene, Demissew Berg, Stefan Aseffa, Abraham |
author_facet | Bekele, Shiferaw Derese, Yohannes Hailu, Elena Mihret, Adane Dagne, Kifle Yamuah, Lawrence Hailu, Tsegaye Ayele, Samuel Beyene, Demissew Berg, Stefan Aseffa, Abraham |
author_sort | Bekele, Shiferaw |
collection | PubMed |
description | BACKGROUND: Antimicrobial resistance is a global concern of increasing significance. Multidrug resistant tuberculosis (MDR-TB) is spreading worldwide. It is important to monitor trends of antimycobacterial resistance. This is particularly true for high TB burden countries such as Ethiopia where disproportionally less drug sensitivity data are reported from. METHODS: The prevalence of drug resistance was assessed with the line probe assay GenoType MTBDRplus in a set of 161 M. tuberculosis strains that were selected from four common lineages and sub-lineages previously identified in Ethiopia. Most of the tested M. tuberculosis isolates had been genotyped by established Spoligotyping and MIRU-VNTR typing methods. RESULTS: The proportion of MDR-TB among the isolates was 3.1%. Mono-resistance was 1.2% to rifampicin and 4.3% to isoniazid, and resistance to either of the two first line drugs was 8.7%. Strains of Lineage 4 had the highest resistance rate (13.6%) followed by Lineage 3 (4.9%). None of the isolates representing Lineages 1 and Lineage 7 were drug resistant. Multidrug resistance among pulmonary TB and TB lymphadenitis clinical isolates was 2.8 and 3.7%, respectively. Drug resistance of strains carrying the most prevalent spoligotype in Ethiopia - SIT149 - was further explored. Stratification by MIRU-VNTR identified one genotype with a high rate of drug resistance against Rifampicin and Isoniazid and circulation of a potential MDR-TB clone is proposed. CONCLUSION: Although the strain selection was not fully randomized, the overall M. tuberculosis drug resistance rate in this strain set was 8.7% while the rate of MDR was 3.1%. In parallel, we identified a sub-lineage that showed a high rate of resistance to both rifampicin and isoniazid. These resistant strains may belong to a clone of M. tuberculosis that is circulating in the highlands of Ethiopia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40794-018-0075-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6280437 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62804372018-12-10 Line-probe assay and molecular typing reveal a potential drug resistant clone of Mycobacterium tuberculosis in Ethiopia Bekele, Shiferaw Derese, Yohannes Hailu, Elena Mihret, Adane Dagne, Kifle Yamuah, Lawrence Hailu, Tsegaye Ayele, Samuel Beyene, Demissew Berg, Stefan Aseffa, Abraham Trop Dis Travel Med Vaccines Research BACKGROUND: Antimicrobial resistance is a global concern of increasing significance. Multidrug resistant tuberculosis (MDR-TB) is spreading worldwide. It is important to monitor trends of antimycobacterial resistance. This is particularly true for high TB burden countries such as Ethiopia where disproportionally less drug sensitivity data are reported from. METHODS: The prevalence of drug resistance was assessed with the line probe assay GenoType MTBDRplus in a set of 161 M. tuberculosis strains that were selected from four common lineages and sub-lineages previously identified in Ethiopia. Most of the tested M. tuberculosis isolates had been genotyped by established Spoligotyping and MIRU-VNTR typing methods. RESULTS: The proportion of MDR-TB among the isolates was 3.1%. Mono-resistance was 1.2% to rifampicin and 4.3% to isoniazid, and resistance to either of the two first line drugs was 8.7%. Strains of Lineage 4 had the highest resistance rate (13.6%) followed by Lineage 3 (4.9%). None of the isolates representing Lineages 1 and Lineage 7 were drug resistant. Multidrug resistance among pulmonary TB and TB lymphadenitis clinical isolates was 2.8 and 3.7%, respectively. Drug resistance of strains carrying the most prevalent spoligotype in Ethiopia - SIT149 - was further explored. Stratification by MIRU-VNTR identified one genotype with a high rate of drug resistance against Rifampicin and Isoniazid and circulation of a potential MDR-TB clone is proposed. CONCLUSION: Although the strain selection was not fully randomized, the overall M. tuberculosis drug resistance rate in this strain set was 8.7% while the rate of MDR was 3.1%. In parallel, we identified a sub-lineage that showed a high rate of resistance to both rifampicin and isoniazid. These resistant strains may belong to a clone of M. tuberculosis that is circulating in the highlands of Ethiopia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40794-018-0075-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-12-04 /pmc/articles/PMC6280437/ /pubmed/30534412 http://dx.doi.org/10.1186/s40794-018-0075-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Bekele, Shiferaw Derese, Yohannes Hailu, Elena Mihret, Adane Dagne, Kifle Yamuah, Lawrence Hailu, Tsegaye Ayele, Samuel Beyene, Demissew Berg, Stefan Aseffa, Abraham Line-probe assay and molecular typing reveal a potential drug resistant clone of Mycobacterium tuberculosis in Ethiopia |
title | Line-probe assay and molecular typing reveal a potential drug resistant clone of Mycobacterium tuberculosis in Ethiopia |
title_full | Line-probe assay and molecular typing reveal a potential drug resistant clone of Mycobacterium tuberculosis in Ethiopia |
title_fullStr | Line-probe assay and molecular typing reveal a potential drug resistant clone of Mycobacterium tuberculosis in Ethiopia |
title_full_unstemmed | Line-probe assay and molecular typing reveal a potential drug resistant clone of Mycobacterium tuberculosis in Ethiopia |
title_short | Line-probe assay and molecular typing reveal a potential drug resistant clone of Mycobacterium tuberculosis in Ethiopia |
title_sort | line-probe assay and molecular typing reveal a potential drug resistant clone of mycobacterium tuberculosis in ethiopia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280437/ https://www.ncbi.nlm.nih.gov/pubmed/30534412 http://dx.doi.org/10.1186/s40794-018-0075-3 |
work_keys_str_mv | AT bekeleshiferaw lineprobeassayandmoleculartypingrevealapotentialdrugresistantcloneofmycobacteriumtuberculosisinethiopia AT dereseyohannes lineprobeassayandmoleculartypingrevealapotentialdrugresistantcloneofmycobacteriumtuberculosisinethiopia AT hailuelena lineprobeassayandmoleculartypingrevealapotentialdrugresistantcloneofmycobacteriumtuberculosisinethiopia AT mihretadane lineprobeassayandmoleculartypingrevealapotentialdrugresistantcloneofmycobacteriumtuberculosisinethiopia AT dagnekifle lineprobeassayandmoleculartypingrevealapotentialdrugresistantcloneofmycobacteriumtuberculosisinethiopia AT yamuahlawrence lineprobeassayandmoleculartypingrevealapotentialdrugresistantcloneofmycobacteriumtuberculosisinethiopia AT hailutsegaye lineprobeassayandmoleculartypingrevealapotentialdrugresistantcloneofmycobacteriumtuberculosisinethiopia AT ayelesamuel lineprobeassayandmoleculartypingrevealapotentialdrugresistantcloneofmycobacteriumtuberculosisinethiopia AT beyenedemissew lineprobeassayandmoleculartypingrevealapotentialdrugresistantcloneofmycobacteriumtuberculosisinethiopia AT bergstefan lineprobeassayandmoleculartypingrevealapotentialdrugresistantcloneofmycobacteriumtuberculosisinethiopia AT aseffaabraham lineprobeassayandmoleculartypingrevealapotentialdrugresistantcloneofmycobacteriumtuberculosisinethiopia |